ESR1 and breast carcinoma: In the screened drug cohort, Raloxifene is a selective estrogen receptor modulator that binds to the estrogen receptor, induces autophagy via the activation of AMPK by sensing decreases in ATP, and promotes cell death in breast cancer cells43.